Study Stopped
Recruiting terminated
Brain Perfusion Assessment in the Acute Phase of Migraine Aura
PERCAM
1 other identifier
observational
25
1 country
1
Brief Summary
The aim of the study is to determine the proportion of patients with change in brain perfusion during the acute phase of migraine attack with aura.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Mar 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 4, 2019
CompletedFirst Posted
Study publicly available on registry
January 30, 2019
CompletedStudy Start
First participant enrolled
March 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 22, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
July 22, 2021
CompletedSeptember 17, 2021
July 1, 2021
2.3 years
January 4, 2019
September 10, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Perfusion pattern of concerned brain areas
Presence or absence of hypo-hyperperfusion using arterial spin labeling. Visual assessments and comparison between hemispheres
1 hour
Secondary Outcomes (1)
Pattern of perfusion and aura duration
12 month
Interventions
the difference of care management and prognosis, an early distinction of migraine aura based on imaging techniques will have a particular interest
Eligibility Criteria
Patients admitted to the hospital with neurological deficit and final clinical diagnosis of migraine with aura (certain probable as defined by The International Classification of Headache Disorders)
You may qualify if:
- Age between greater than or equal to 18
- Able to undergo MRI during migraine aura
You may not qualify if:
- Pregnant females
- Contraindications towards MRI scanning
- History of epilepsy, psychiatric disease, or any other neurologic disease (brain tumors, stroke..).
- Presence of abnormalities on the MRI that could explain the neurological deficit.
- Adults under guardianship or trusteeship
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU Nantes
Nantes, 44000, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Solene de Gaalon, Dr
Nantes University Hospital
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 4, 2019
First Posted
January 30, 2019
Study Start
March 1, 2019
Primary Completion
June 22, 2021
Study Completion
July 22, 2021
Last Updated
September 17, 2021
Record last verified: 2021-07